HeartBeam Granted Patent for 12-Lead Electrocardiogram (ECG) Patch Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias
The global ECG patch monitor market, estimated to reach $4.8B by 2030, is currently limited to arrhythmia detection via the use of single-lead ECG devices.
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced today that its patent for a 12-lead electrocardiogram (ECG) patch monitor intended for detection of acute coronary syndrome (ACS) and cardiac arrhythmia was issued by the United States Patent and Trademark Office. The innovation builds on HeartBeam’s growing intellectual property portfolio enabling 12-lead ECG diagnostics outside of a medical setting.
The global ECG patch monitor market, estimated to reach $4.8B by 2030, is currently limited to arrhythmia detection via the use of single-lead ECG devices. By elevating patch monitor technology with a synthesized 12-lead ECG, HeartBeam can aid physicians in both arrhythmia detection and ACS diagnosis including myocardial infarction (heart attack) and angina.
“This patent provides additional intellectual property protection for our breakthrough ECG patch technology, offering 12-lead ECG capability in the form of a simple patch that is similar in size and shape to existing single-lead ECG patch monitors in the market today,” said HeartBeam CEO and Founder Branislav Vajdic, PhD. “Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care and could have a disruptive effect on the ECG patch market with its ischemia detection capability.”
The newly issued patent (No. 11,419,538 B2) expands on the HeartBeam’s previously granted US patent (No. 11,071,490 B1) for a 12-lead ECG patch monitor technology. The patch patent follows HeartBeam’s already granted core patents for remote detection of heart attacks. These two issued patch patents significantly increase HeartBeam’s intellectual property footprint, and they further widen the impact HeartBeam’s technology could have on cardiac patients and their physicians.
“The ECG monitors available today are primarily used for detection of abnormal heart rhythms associated with atrial fibrillation or syncope,” said Martin Burke, DO, FACC, cardiac electrophysiologist and chief scientific officer of the CorVita Science Foundation, which holds The Rory Childers Electrocardiology Research Center and Fellowship program. “A 12-lead ECG patch would provide additional information to aid in diagnosing conditions such as ACS or more specific arrhythmias that current single-lead patches cannot accurately detect.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our in our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005195/en/